Drug against pneumonia

 

(57) Abstract:

Developed drug against pneumonia - polydisulfide Gallic acid. The drug is more effective than used in practice unithiol. table 2.

The invention relates to biology and medicine and relates to means against pneumonia.

Know the use for the treatment of pneumonia salt drugs [1], acetylcysteine [2], ribonuclease [3].

Wide use for the treatment of pneumonia received the drug unithiol [4] (prototype). However, its effect in the treatment of pneumonia is not effective.

The problem to which the invention is directed, is the extension of the range of products with a therapeutic effect against pneumonia. The problem is solved by the use as a drug against pneumonia polydisulfide Gallic acid formula

< / BR>
where

n = 12-16.

Polydisulfide Gallic acid obtained by condensation of Gallic acid with odnoklasniki grey.

Example. In the reaction flask 17.0 g (0.1 M) of Gallic acid, 150-200 ml of previously dried 0-, m-, p-xylene and with vigorous stirring, 13.5 g (8.1 oz) odnoklasniki sulfur within 15-20 is. At the end of the reaction the precipitate of polydisulfide Gallic acid is filtered off, washed with o-, m-, p-kisslola, and then with water until a negative reaction to chlorine ion. The synthesis time of 30 h, the output of 92-95%, So pl. = 260-262oC discrepancies. The reaction scheme

< / BR>
n = 12-16.

Polydisulfide Gallic acid - substance light yellow color.

The elemental composition, wt. %:

Found: C 38,60; H 1,33; S 24,59;

Calculated: C 36,21; H 1,72; S 27,59.

Molecular weight (cryoscopy in diphenyl) found 3600.

Infrared absorption spectrum (V cm-1):

480 - S-S -, 870-C-H-pentamidine benzene,

1230 - S-C-OH, 1480-benzene ring, 1630-COOH, 3300-OH polymer.

Evaluation of therapeutic action of the drug was carried out on models of inflammation of the lungs at 24 lab rats "Wister" weighing 150-200 g Inflammatory process in the lungs was simulated by introducing a sterile nylon filament with a diameter of 0.25 mm and a length of 2.5 cm into the trachea of laboratory animals. Treatment was started within 14 days after the modeling of the inflammatory process in the lungs. The drugs were injected intraperitoneally for 14 days in 10 injections for treatment. Unithiol was introduced in the form of a 5% solution at a dose of 12.5 mg per 100 g of rat, polydisulfide Gallo is of lungs after treatment the animals were killed by arterial blood-letting from the carotid artery. From blood was isolated serum was prepared hemolysate. After slaughter, the animals were isolated pulmonary-cardiac complex and produced broncho-alveolaris washed away by 6-8 times washing the lungs through the trachea with 10 ml of saline. Wash was centrifuged at 600 rpm for 15 min and supernatant was collected, which was used for biochemical studies. In parallel, we investigated a group of animals in which the inflammatory process was developed without treatment against intraperitoneal administration of saline. As a control used a group of 10 healthy animals. Research methods included the identification of key system components proteolysis and free-radical oxidation of blood and broncho-alveolare secret. Serum was investigated anastasopoulou activity (AEP) [5] , - 1-inhibitorbuying ( -1-MIP) and-2-macroglobulin [6] , lipids phosphoroamidites method, diene conjugates (DC) and dircetory (D) [7], the level of malondialdehyde and TBA-active products (TBCAP) [8], katalizatorow activity [9], ceruloplasmin (CP) [10].

In the hemolysate was determined katalizatorow and peroxidation activity (PA) [11] , in bronchoalveolar secret studied with isopogon activity and CPU usage. Statistical processing of results was performed using criterion Student.

Results therapeutic effect on pneumonia claimed and adverse drug are presented in table. 1 and 2.

In the serum the use of drugs has led to a decrease in the content of products of lipid peroxidation. When using unithiol number of MDA decreased by 30%, and polydisulfide Gallic acid 32% and 40% reduction alactolyticus activity of serum. In bronchoalveolar secret when using polydisulfide Gallic acid observed a threefold reduction in the flushing of diene conjugates, ceruloplasmin more than 2 times, while in the presence of unithiol only 33%.

Thus, polydisulfide Gallic acid is an effective drug that reduces the activation of free radical oxidation and proteolysis in inflammatory lung disease.

Sources of information used in the preparation of the description of the invention

1. Komarov F. I., Danilin, I., Gulyaeva, F. E. Clinical medicine, 1980, No. 4, S. 19-24.

2. Violin R. S., lesser black-backed gull C. E., Kimanis A. A., Pharmacology, 1971, -1, S. 98-100.

3. ASS="ptx2">

5. Ogloblin O. G., Platonov, L. C., L. Myasnikov Century Questions of medical chemistry, 1980, No. 3, S. 387-392.

6. Particula C. F., Pashina ie, Questions of medical chemistry, 1979, No. 4, S. 494-499.

7. Gavrilov Century B. , Meskarune M. Laboratory work, 1983, No. 3, S. 33-35.

8. Asakawa, T., Matsushitus. Lipids 1980, 15, N 3, p. 137-140.

9. Korolyuk M. A., Ivanova L,I., Mayorova, I., Tokarev C. E. Laboratory business, 1986, No. 1, S. 16-19.

10. Kolb Century BC, Kamyshnikov C. S. Handbook of clinical chemistry, Minsk: Belarus, 1982, S. 201-204.

11. Popov, C. , Nalkowska L. A. Hygiene and sanitation, 1971, No. 10, S. 89-91.

Drug against pneumonia, characterized in that it is polydisulfide Gallic acid formula

< / BR>
where n = 12 to 16.

 

Same patents:

The invention relates to biology and medicine and relates to means against radiation damage

Drug against shock // 2108790
The invention relates to biology and medicine and relates to a medicinal product that protects from shock

The invention relates to the oligoesters, method for their production and compositions on their basis, which possess significant activity against the virus of human immunodeficiency and is used for the treatment of acquired immunodeficiency syndrome (AIDS)

FIELD: medicine.

SUBSTANCE: method involves drying injured zone after having removed dental deposit and additional treating cement surface in inflammation zone with citric acid solution of 0.1 mMole/l concentration during 5 min, and then with 0.06% Chlorohexidine solution and Nikiforov mixture. Sulfacrylate is placed into periodontium pocket as glue periodontial bandage and the lesion focus is treated with ultrasound of 26.5 kHz during 3 s.

EFFECT: accelerated treatment course; activated reparative processes in periodontium; improved mechanical strength; accelerated polymerization in glue bandage.

2 tbl

FIELD: medicine.

SUBSTANCE: novel biomaterials consist of combination of sulphated hyaluronic acid and deacetylated hellane for application as highly efficient barrier for prevention of post-operation commissures in operation in abdominal, pelvic areas and, first of all, on spine.

EFFECT: increase of application efficiency.

16 cl, 1 dwg, 2 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: invention refers to high-molecular compounds for medical purposes. Water-soluble polymeric complexes of antiviral agent arbidol of general formula: are described, where: Arb - arbidol: ethyl ester 6-bromo-4-dimethyl-aminometil-1-methyl-5-oxy-2-feniltiometilindolinil-3-carboxylic acid hydrochloride monohydrate; m1=100-(m2+m3) mol %; m2=(7.6-9.8) mol %; m3=(11.5-13.6) mol %; content of Arb=26.4-32.1 wt %.

EFFECT: obtained water-soluble polymeric complexes of arbidol may find application in pharmacology, as they can serve as basis for new effective and safe antiviral drugs and their dosage forms.

1 cl, 6 ex, 4 tbl, 2 dwg

Transdermal plaster // 2445084

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly pharmaceutical preparations, namely: plasters for transdermal application. Substance of invention consists in the fact that a transdermal plaster representing a matrix system and comprising a lining layer, a matrix layer and a lightproof protective coating in the following proportions is produced: 6.72 wt % of hypoxene substance, 15.11 wt % of sodium metabisulphite in propylene glycol with 0.067% of sodium metabisulphite, as well as 56.0 wt % of 95% ethanol and 22.17 wt % of PVP K30. The plaster aims at the transdermal introduction of hypoxene. A plaster area is 25 cm2.

EFFECT: offered plaster used for treating and preventing chronic diseases allows avoiding the problems related to oral administration, improves patient compliance, enables prolonged maintenance of the hypoxene concentration; it is suitable for purposes of combination therapy.

6 dwg, 1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: what is presented is a group of inventions which refers to medicine, namely dermatology. The group of inventions involves the use of a known compound as an agent for preparing a composition for stimulating and/or accelerating fibroblast proliferation in vivo and ex vivo, and respectively wound healing, as a wound healing dressing containing such compound. This compound represents a copolymer of 2-methyl-2-[(1-oxo-2-propenyl)amino]-1-propane sulfonic acid salt and propenoic acid 2-hydroxyethyl ester. It may be used either separately or in a combination with the other active substances for inducing or accelerating wound healing. This compound either separately, or in a combination with the other active substance may be introduced on the wound directly and a surrounding area or mucous membranes by local application. The presents inventions also find application for making dressings on the basis of hydrogels and hydrocolloids which contain said copolymer. For the purpose of the use in vivo, the given copolymer is used in the composition or in the dressing for wound healing that promotes better improvement of wound surface regeneration and healing stimulation.

EFFECT: use of the copolymer ex vivo is effective for autologous skin or skin-epidermal transplants as that enables accelerating fibroblast proliferation.

3 tbl

FIELD: pharmacology.

SUBSTANCE: invention relates to the high-molecular weight compounds of the medical purpose, more specifically to new synthetical sulfo-containing homo- and copolymers 2-acrylamido-2-methylpropansulfoacid with its own bioactivity that can be used in pharmacology in the capacity of the future-proof antiviral agents or can serve as the basis for the new effective and harmless antiviral medicinal agents and its pharmaceutical forms. The homo- and copolymers 2-acrylamido-2-methylpropansulfoacid of the stated below formula are obtained by the radical heterophase (co)polymerization in the ethanol at 70°C within 24 hours. The homo- and copolymers 2-acrylamido-2-methylpropansulfoacid have the molecular weight MM=(40-70)⋅103.

where

,

m=100 mol. %, n=0;

,

m=(22.8-58.1) mol. %, n=(77.2-41.9) mol. %.

EFFECT: invention allows to get nontoxical homo- and copolymer 2-acrylamido-2-methylpropansulfoacid with its own antiviral activity against the influenza viruses H3N2, H1N1.

1 tbl, 2 ex

Up!